DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Gardner KM, Dorcy KS. et al
Use of gemtuzumab ozogamicin for the treatment of relapsed or refractory acute myeloid leukemia (AML) or acute promyelocytic leukemia (APL) in an expanded access setting at our cancer consortium.
Blood 2018;
132 (supplement 1) 2710
Access:
We do not assume any responsibility for the contents of the web pages of other providers.